If you or a loved one has been taking Reglan and notice involuntary muscle movements—like lip smacking, grimacing, or rapid blinking—these could be early signs of tardive dyskinesia. The medical community has long recognized that prolonged use of metoclopramide can increase the risk of this movement disorder. This page outlines the key symptoms to track and what the science says about monitoring your health.
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information explicitly limits use for gastroesophageal reflux to 4 to 12 weeks, and states that Reglan has not been shown to be safe or effective for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding total treatment duration longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of tardive dyskinesia (TD) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The most serious risk associated with Reglan is tardive dyskinesia, a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA requires a boxed warning on the label stating that metoclopramide, including Reglan, can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also notes that Reglan may suppress or partially suppress signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the label instructs prescribers to use the drug for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. This is consistent with the known pharmacology of metoclopramide as a dopamine receptor blocker. The label warns that concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome should be avoided, and Reglan should not be used in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients in California who have developed TD after using Reglan, several legal considerations arise. The statute of limitations for personal injury claims in California is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving prescription drugs, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their TD. Given that TD can develop insidiously and may be masked by the drug itself, the timeline between exposure and documented harm is critical. The label states that risk increases with duration and cumulative dose, but TD can occur even after short-term use, and symptoms may appear during treatment or after discontinuation. Patients who used Reglan for longer than 12 weeks, or who were not warned about TD risk, may have stronger claims regarding inadequate warnings.
The adequacy of warnings is a central issue. The FDA-mandated boxed warning clearly states the risk of TD, the need for short-term use, and the contraindication in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, patients may argue that their prescribing physician did not adequately communicate this risk, or that they were not informed about the importance of limiting treatment duration. The label also notes that Reglan is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), which may be relevant for cases involving off-label use in children. Attorney considerations for affected patients include gathering medical records documenting Reglan prescriptions, duration of use, and the diagnosis of TD. Expert testimony may be needed to establish causation and to address whether the prescribing physician deviated from the standard of care by failing to monitor for TD or by continuing treatment beyond 12 weeks. The statute of limitations in California requires prompt action; delays in filing could bar recovery. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances, including the date of TD diagnosis and the date they first learned of the link to Reglan. In summary, Reglan carries a well-documented risk of tardive dyskinesia, with the FDA label emphasizing short-term use and immediate discontinuation if symptoms appear. For California patients, the statute of limitations and the adequacy of warnings are key factors in potential legal claims. The evidence supports that prolonged use and cumulative dosage increase risk, and that the drug's labeling provides clear guidance to prescribers and patients.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For prescription drug claims, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their tardive dyskinesia. It is crucial to act promptly to preserve legal rights.
Yes, while the risk of tardive dyskinesia increases with duration of treatment and total cumulative dosage, the FDA label warns that TD can occur even after short-term use. Symptoms may appear during treatment or after discontinuation. The label advises using Reglan for the shortest duration necessary and to immediately discontinue if signs of TD develop.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.